MRUS Merus BV

Price
$51.38
Increased by +2.15%
Dollar volume (20D)
21.80 M
ADR%
3.23
Earnings report date
Feb 26, 2025
Shares float
62.68 M
Shares short
8.85 M [14.12%]
Shares outstanding
68.46 M
Market cap
3.44 B
Beta
1.11
Price/earnings
N/A
20D range
49.27 54.95
50D range
46.65 54.95
200D range
33.60 61.61

MerusN. V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.

Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.

In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers.

The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Aug 1, 24 -0.81
Decreased by -22.73%
-0.76
Decreased by -6.58%
May 8, 24 -0.59
Increased by +31.40%
-0.81
Increased by +27.16%
Feb 28, 24 -1.04
Increased by +42.54%
-0.74
Decreased by -40.54%
Nov 2, 23 -0.43
Increased by +18.87%
-0.73
Increased by +41.10%
Aug 7, 23 -0.66
Decreased by -407.69%
-0.88
Increased by +25.00%
May 4, 23 -0.86
Decreased by -100.00%
-1.02
Increased by +15.69%
Feb 28, 23 -1.81
Decreased by -432.35%
-0.83
Decreased by -118.07%
Nov 3, 22 -0.53
Decreased by -35.90%
-0.63
Increased by +15.87%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 11.77 M
Increased by +6.70%
-99.91 M
Decreased by -334.14%
Decreased by -848.67%
Decreased by -306.89%
Jun 30, 24 7.33 M
Decreased by -30.01%
-50.04 M
Decreased by -56.22%
Decreased by -682.52%
Decreased by -123.21%
Mar 31, 24 7.89 M
Decreased by -41.56%
-34.46 M
Increased by +13.30%
Decreased by -436.76%
Decreased by -48.36%
Dec 31, 23 8.94 M
Decreased by -16.19%
-60.15 M
Increased by +26.62%
Decreased by -672.93%
Increased by +12.44%
Sep 30, 23 11.03 M
Increased by +67.65%
-23.01 M
Increased by +6.51%
Decreased by -208.57%
Increased by +44.24%
Jun 30, 23 10.48 M
Decreased by -17.41%
-32.03 M
Decreased by -460.61%
Decreased by -305.78%
Decreased by -578.76%
Mar 31, 23 13.50 M
Increased by +15.82%
-39.74 M
Decreased by -110.35%
Decreased by -294.40%
Decreased by -81.61%
Dec 31, 22 10.67 M
Decreased by -27.49%
-81.97 M
Decreased by -468.42%
Decreased by -768.54%
Decreased by -683.88%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY